New antibody MTX-439 enters first human trial for diabetic kidney disease

NCT ID NCT07473323

Recruiting now Disease control Sponsor: Mediar Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called MTX-439, an antibody that blocks a protein linked to kidney scarring. It will be given to healthy volunteers and people with diabetic kidney disease to check for safety and how the body processes it. The study is small (88 participants) and aims to find a safe dose for future testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MTX-439 (an antibody that targets a protein called SMOC2)
What this could lead to: If successful, this could point toward a new treatment option for diabetic kidney disease by targeting a protein involved in scarring.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (88 people) and may not lead to a working treatment. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC KIDNEY DISEASE HEALTHY ADULT PARTICIPANTS

Contacts and locations

Locations

Doherty Clinical Trials
RECRUITING

Melbourne, Victoria, 3002, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.